Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Vectura Limited v. GlaxoSmithKline LLC et al
Case Number:
1:16-cv-00638
Court:
Nature of Suit:
Judge:
Firms
-
October 05, 2020
Fed. Circ. Mulls New Trial In Vectura's $107M Inhaler IP Win
A Federal Circuit judge peppered Vectura Limited's counsel with tough questioning Monday, suggesting that attorneys for the U.K.-based pharmaceutical company defied a Delaware federal court's instructions during jury trial last year, which may warrant a retrial of the nearly $107 million verdict in an inhaler patent dispute.
-
September 12, 2019
Vectura Gets $10M Added To $90M Inhaler IP Award
A Delaware federal judge on Thursday granted British pharma company Vectura's request for $10.5 million in supplemental damages in a case in which a jury found GlaxoSmithKline willfully infringed a patent covering inhalers, though the judge denied Vectura's bid for an additional $33 million in enhanced damages.
-
June 27, 2019
Vectura Demands Another $44M In Inhaler IP Clash
British pharma company Vectura has asked a Delaware federal judge to pile another nearly $44 million onto the damages GlaxoSmithKline owes after a jury found GSK willfully infringed a patent covering inhalers, saying the company is still selling the products and doesn't plan to stop.
-
June 14, 2019
GSK Calls $90M Inhaler IP Damages 'Wildly Inflated'
Vectura Ltd. won an $89.7 million patent infringement verdict against GlaxoSmithKline LLC by relying on flawed tests and inflating damages, GSK has told a Delaware federal judge in hopes of undoing its loss.
-
May 03, 2019
GlaxoSmithKline Hit With $89.7M Verdict For Inhaler IP
A federal jury in Delaware on Friday found that GlaxoSmithKline LLC and Glaxo Group Ltd. owe $89.7 million to U.K.-based Vectura Limited for infringing a single claim of a patent covering features of three important Glaxo inhalers for treating chronic obstructive pulmonary disease.